Kyntra Bio, Inc.: Maxim Group initiates coverage with buy rating; target price $35
KYNB•Maxim Group initiated coverage of Kyntra Bio, Inc. with a buy rating and a $35 target price.
Related News
Skydance settles cash tender offers for $2.4 billion of WBD notes after acquisition closes
SKYD•
Wave Life Sciences CEO joins Chardan healthcare conference RNA medicines panel
WVE•
Magnera enters CRADA with US Army Research Lab on next-generation battery separators
MAGN•
Biodexa enrolls 100th patient in Serenta Phase 3 eRapa trial
BDRX•
NeuroSense sets Nov. 10 Nasdaq panel hearing after delisting notice over market value rule
NRSN•